# Emerald Development Managers

> Emerald Development Managers is a VC fund backing Health Care and Medical. See 40 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 40
- Last investment: Dec 2025
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/emerald-development-managers-lp
- Website: http://www.emeraldmanagers.com/

Emerald Development Managers is a venture capital firm focusing on early-stage growth equity investments. The firm deals sourced from decades-long relationships with academic institutions, operating managers, angels, and like-minded VCs. In addition to capital, they bring experience, discipline, critical thinking, financing expertise, andsignificant hands-on involvement to the companies and support, and often refer to what they do as providing mentor capital.Founded in 1994 and is based in New York, NY, USA.

## Contacts

5 contacts available for Emerald Development Managers. Shizune tracks 5 team members at Emerald Development Managers. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/emerald-development-managers?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 9 | 23% |
| Medical | 7 | 18% |
| Software | 7 | 18% |
| Biotechnology | 7 | 18% |
| Cyber Security | 7 | 18% |

51 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 12 | 30% |
| Seed | 9 | 23% |
| Series B | 6 | 15% |
| Funding Round | 4 | 10% |
| Series C | 3 | 8% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 24 | 60% |
| Italy | 1 | 3% |
| Canada | 1 | 3% |
| United Kingdom | 1 | 3% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Neil Cohen | Founder and Chairman | 3 | https://shizune.co/investors/profile/neil-cohen-311f |
| Charles Collins | Managing Director | 2 | https://shizune.co/investors/profile/charles-collins |
| Ian Tolfree | Entrepreneur-in-Residence | 0 | https://shizune.co/investors/profile/ian-tolfree |
| Joshua Smith | Vice President, Investor Relations | 0 | https://shizune.co/investors/profile/joshua-smith-43d1 |
| Neil Cohen | Founder and Chairman | 0 | https://shizune.co/investors/profile/neil-cohen-3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Random Power | Random Power develops a random bit generator for key generation. It also provides secure, cost-effective, robust, and tiny devices for the IoT, secure computing, gambling, simulation of complex processes, and training in artificial intelligence algorithms and markets with significant expected growth to let users generate and transmit randombitstreams while varying a variety of system parameters.The company's bit generator is based on a silicon device, with all of the advantages connected to the micro-electronics advances; the source of randomness is endogenous, and this is a genuine paradigm shift with respect to existing devices, providing simplification and robustness to the system. | $3M | Seed | Dec 10, 2025 |  |
| Una Software | Una Software involves working together and putting decisions into practice. Una Software develops products to facilitate revenue orchestration. | $4.4M | Seed | May 08, 2025 |  |
| Uviquity | Uviquity is a firm that wants to encourage safety for their clients. The company is based in Raleigh, North Carolina, in the United States. | $6.6M | Seed | May 07, 2025 |  |
| Proscia | Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team oftechnologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. | $50M | Series D | Mar 19, 2025 |  |
| Uviquity | Uviquity is a firm that wants to encourage safety for their clients. The company is based in Raleigh, North Carolina, in the United States. | $6.7M |  | Sep 05, 2024 |  |
| Uviquity | Uviquity is a firm that wants to encourage safety for their clients. The company is based in Raleigh, North Carolina, in the United States. | $6.7M | Seed | Sep 05, 2024 |  |
| Proscia | Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team oftechnologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. | $9M | Series C | Mar 13, 2024 |  |
| ETCH | ETCH commercializes a chemical process that generates low-cost hydrogen by splitting natural gas into hydrogen and solid carbon. The process can be powered by either natural gas, hydrogen, or electricity. Carbon generated by the process is pure and can be stored in environmentally benign facilities. | $7.5M | Seed | Jul 25, 2023 |  |
| Cyware | Cyware Labs provides cyber fusion solutions to help businesses detect and stop advanced cyberattacks.Cyware offers the technology organizations need to build a virtual cyber fusion center. With separate but integrated solutions including an advanced threat intel platform (TIP), vendor-agnostic security automation (SOAR), and security casemanagement, organizations are able to increase speed and accuracy while reducing costs and analyst burnout. Cyware's virtual cyber fusion solutions make secure collaboration, information sharing, and enhanced threat visibility a reality for enterprises, sharing communities (ISAC/ISAO), MSSPs, and government agencies of all sizes and needs. | $30M | Series C | Jun 29, 2023 |  |
| Transcend Therapeutics | Transcend Therapeutics is a clinical-stage biotechnology company focused on developing rapid-acting treatments for neuropsychiatric diseases. The company aims to address mental health conditions such as post-traumatic stress disorder (PTSD) and major depressive disorder (MDD), particularly for patients who do not respond to existing therapies. Thecompany’s lead program, TSND-201 (methylone), is being developed as a next-generation neuroplastogen designed to deliver fast and durable therapeutic effects. Its research emphasizes innovative psychoactive compounds that can improve outcomes while minimizing common limitations of traditional psychiatric medications. Backed by venture funding and an experienced leadership team with multiple FDA approvals, Transcend Therapeutics continues to advance clinical trials and expand its pipeline of mental health treatments. | $40M | Series A | Feb 23, 2023 |  |

10 of 40 investments shown.

## Co-investors
- [CIG Spectrum Capital](https://shizune.co/investors/profile/cig-spectrum) — VC Fund, 8 deals together
- [Eniac Ventures](https://shizune.co/investors/profile/eniac-ventures) — VC Fund, 5 deals together
- [Evolution Equity Partners](https://shizune.co/investors/profile/evolution-equity-partners) — VC Fund, 5 deals together
- [Razor's Edge Ventures](https://shizune.co/investors/profile/razors-edge-fund) — VC Fund, 4 deals together
- [Robin Hood Ventures](https://shizune.co/investors/profile/robin-hood-ventures) — VC Fund, 4 deals together
- [RRE Ventures](https://shizune.co/investors/profile/rre-ventures) — VC Fund, 4 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Emerald Development Managers invest in?

Emerald Development Managers invests primarily in Health Care, Medical and Software startups, most often at Series A and Seed stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Emerald Development Managers?

Public channels for Emerald Development Managers include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Emerald Development Managers?

The team at Emerald Development Managers includes Neil Cohen (Founder and Chairman), Charles Collins (Managing Director) and Ian Tolfree (Entrepreneur-in-Residence). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co